Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Quidel to Present at Upcoming Conferences


Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the following upcoming conferences:

Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will present on the specified days with question-and-answer sessions scheduled immediately following each presentation. During the presentations, the company will discuss business and financial developments and trends. The company's statements may contain or constitute material information that has not been previously disclosed.

A live webcast and audio archive of each presentation will be available via the Investor Relations section of the company's website at http://ir.quidel.com or by clicking the links below.

Piper Jaffray: https://event.webcasts.com/starthere.jsp?ei=1271732&tp_key=0c156c3f36

Evercore ISI: http://wsw.com/webcast/evercore4/qdel

Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast. A replay of the webcast will also be available on the company's website for 30 days.

About Quidel Corporation

Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage® and InflammaDry® leading brand names, as well as under the new Solana®, AmpliVue® and Lyra® molecular diagnostic brands, Quidel's products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's recently acquired Triage® system of tests comprises a comprehensive test menu that provides rapid, cost-effective treatment decisions at the point-of-care (POC), offering a diverse immunoassay menu in a variety of tests to provide diagnostic answers for quantitative BNP, CK-MB, d-dimer, myoglobin, troponin I and qualitative TOX Drug Screen. Quidel's research and development engine is also developing a continuum of diagnostic solutions from advanced immunoassay to molecular diagnostic tests to further improve the quality of healthcare in physicians' offices and hospital and reference laboratories. For more information about Quidel's comprehensive product portfolio, visit quidel.com.


These press releases may also interest you

at 11:00
As part of the "Stay in & SLING" initiative, SLING TV will stream Grand Ole Opry's 4,917th consecutive Saturday night concert with music legends Vince Gill and Amy Grant. The event is part of the SLING TV free experience, with no paid SLING TV...

at 10:05
Merck , known as MSD outside the United States and Canada, today announced the presentation of results from the VICTORIA trial, a Phase 3 study evaluating the efficacy and safety of its investigational drug vericiguat, an orally administered soluble...

at 10:00
Today, Greg Ott, the CEO of Nav, a service that gives business owners the fastest, easiest and most trusted path to financing, sent a letter to Congressional leaders offering Nav's support in overcoming the unprecedented challenges being experienced...

at 10:00
Since 1952, the Luther Automotive Group has served Minnesota drivers and communities, and nothing has changed. Today, the group announced the addition of new online sales, service tools and special accommodations to ensure essential workers have safe...

at 09:55
New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca's FARXIGA (dapagliflozin) reduced the incidence of the primary composite endpoint of...

at 09:07
In response to the global COVID-19 pandemic, Principal of DigitalMarketer, Roland Frasier will host Business Lunch To Go, a live version of his podcast Business Lunch. Frasier will interview a different celebrity daily on his Facebook page starting...



News published on 14 november 2019 at 18:05 and distributed by: